1 Hour Till Beast MODE!!

Today's Stock Alert Is (NASDAQ:CTXR)      Good morning traders,    If you haven't done so pull up (NASDAQ:CTXR) and start doing your research. You know that we are a fan of a good looking chart and CTXR chart's is looking pretty sweet!  Not to mention this stock is carrying a $4.00 Price target from 2 different analysts and calling it a strong buy.   Keep (NASDAQ:CTXR) IS at the the top of our list for the open. The stock is already up 13% from yesterday and has traded over 200k shares.. The market isn;t even open yet!    Can we see another massive rally like over previous alert this week?    (NASDAQ:CTXR) To the moon!  Full Company Profile below:  Is this Emerging NASDAQ Company Poised to be the Next Big Breakout Play in the Biotech Arena? Momentum looks HOT right now! Greetings All, After a slew of takeover deals in 2023, the interest in biotech and biopharma began in 2024 with some great promise. Innovation is thriving in this growing space and big winners have continuously emerged.  One company going underfollowed on the NASDAQ may be the crème of the top and should be high on your radar! Add Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) to your watch list! Trading in mere pennies, CTXR is a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products. Immediate reasons why you should have your eyes on CTXR right now include a "BUY" rating at BarChart.com, and a "STRONG BUY" rating at NASDAQ.com with two notable analysts rating the stock: H C WAINWRIGHT MAXIM GROUP,LLC   AND… NASDAQ.com has a $4 price target listed! In the last few weeks, CTXR has seen some big gains before slightly pulling back. Shares moved from around 60 cents to over $1! It looks like the stock may be on an upward move again. So, what is CTXR doing and why does it matter? Citius Pharma's diversified pipeline includes two late-stage product candidates.  At the end of 2023, Citius completed enrollment in a Phase 3 pivotal superiority trial of Mino-Lok® , an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.  The company resubmitted the Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), in early 2024, and announced plans to form Citius Oncology , a standalone publicly traded company with LYMPHIR as its primary asset.  What is LYMPHIR? LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and Periphel T-cell Lymphoma (PTCL). In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.  The company believes LYMPHIRTM is a novel targeted oncology asset with an attractive near-term revenue opportunity and a substantially de-risked path to support commercial success.  What is Mino-Lok? Mino-Lok® is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs).  CRBSIs/CLABSIs are life-threatening conditions , especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients where venous access presents a challenge. Mino-Lok® is intended to salvage the CVC, avoiding the need to remove and replace the infected catheter. Currently, there are few alternatives to removing and replacing a CVC once it becomes infected! Program Highlights ►Mino-Lok® is the first & only therapy under investigation to salvage infected CVCs ► In a Phase 2b trial, Mino-Lok® demonstrated a 100% efficacy rate in salvaging colonized CVCs; Mino-Lok® had no significant adverse events compared to an 18% serious adverse event rate when infected CVCs were removed and replaced. Learn more… ► A multicenter Phase 3 pivotal superiority trial is currently underway. Learn more… ►Mino-Lok® was granted QIDP and Fast Track designation by the FDA and has patent protection through 2024 and formulation patent protection through 2036! ►Citius licensed the worldwide rights to Mino-Lok® from The University of Texas MD Anderson Cancer Center CTXR had some pretty big news last week…. CTXR announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas.  Citius is collaborating with the University of Minnesota (UMN) in this investigator-initiated study. This Phase 1 dose-finding study to evaluate LYMPHIR prior to CAR-T therapies tisagenlecleucel (KYMRIAH®), axicabtagene ciloleucel (YESCARTA®), or lisocabtagene maraleucel/BREYANZI®), in patients with B-cell lymphomas (BCL) (NCT0485525) was initiated in May 2021 and has been expanded to include City of Hope.  Enrollment is underway for patients diagnosed with relapsed or refractory BCL, for which treatment with CAR-Ts is planned, and who are considered at high risk for progression after CAR-T therapy. The ongoing study, led by Dr. Veronika Bachanova at the University of Minnesota (UMN), will include an additional study site at City of Hope (COH), a world-renowned cancer treatment and research institution, with Dr. Matthew Mei as the principal site investigator at COH.  City of Hope is one of ONLY 53 National Cancer Institute (NCI)-designated comprehensive cancer centers in the U.S. "We are encouraged by the scientific community's interest in exploring the potential benefits of LYMPHIR beyond cutaneous T-cell lymphoma, for which a Biologics License Application is currently under review by the FDA. We are very excited to support UMN's expansion of its study to City of Hope as distinguished oncologists Dr. Bachanova and Dr. Mei conduct innovative research to evaluate LYMPHIR in combination with CAR-T treatment," stated Dr. Myron Czuczman, Chief Medical Officer of Citius. "This first-of-its-kind study will evaluate the potential value that transient depletion of T-regs within the tumor microenvironment by LYMPHIR has upon CAR-T-based anti-tumor activity," stated Dr. Myron Czuczman, Chief Medical Officer of Citius. Other big news… CTXR Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma T he U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Company's Biologics License Application (BLA) for LYMPHIR™ (denileukin diftitox), an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The FDA has assigned a PDUFA goal date of August 13, 2024. Leonard Mazur, Chairman and CEO of Citius has said, "We believe there remains a critical unmet need for an additional viable treatment option for patients with relapsed or refractory CTCL as current therapies are non-curative. We are grateful for the FDA's vital support for rare disease drug development as we work to expand treatment options for patients with cutaneous T-cell lymphoma. We look forward to the FDA's decision and the potential benefit LYMPHIR may provide patients with relapsed or refractory CTCL." In summary… Biotech… it's one of the most thrilling arenas where a simple news announcement about a study or trial can send shares exploding.  And then there's the potential of a holy grail FDA announcement…. This is usually what keeps investors watching biotech companies closely. Finding remarkable companies in this space that are relatively anonymous compared to bigger players in the industry is what savvy investors hunt for. One emerging biotech company not to ignore right now is Citius Pharmaceuticals, Inc. (NASDAQ: CTXR). CTXR has BULLish ratings, a $4 price target, and two LATE-STAGE product candidates.  Keep an eye out for developments!  You never know what could be a catalyst to drive a rally! OH… and to reiterate… a whopping $26.5M has been invested by the company's founders!! With a diversified pipeline and products addressing some of the world's most addressable markets, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a biotech company that may be trading at a supreme premium right now….     Disclaimer We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Huge Alerts nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Huge Alerts. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Huge Alerts makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Some of the content on this website contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results. Generally, the information regarding a company profiled or discussed on this website is provided from public sources hugealerts.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Huge Alerts has no obligation to update any of the information provided. Huge Alerts, its owners, officers, directors, contractors and employees are not responsible for errors and omissions. From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Huge Alerts encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content.Huge Alerts, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Huge Alerts control, endorse, or guarantee any content found in such sites. Huge Alerts does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Huge Alerts, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Huge Alerts, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Huge Alerts uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm. Income Disclaimer Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions.huge alerts has not been compensated for this email

 

1389 Center Dr
Park City UT 84098
USA

Unsubscribe   |   Change Subscriber Options